On the Fibrinolytic System in Aged Rats, and Its Reactivity to Endotoxin and Cytokines

Summary

Aged rats are more susceptible to endotoxin-induced effects, including microthrombosis and platelet aggregation, than are young rats. To investigate whether changes in the fibrinolytic system might be involved, we investigated the fibrinolytic activity in plasma euglobulin fractions and tissues (lung and heart) of young (6-months old) and aged (24-months old) rats under baseline conditions and after challenge with endotoxin. Aged rats had lower plasma levels of tissue-type plasminogen activator (t-PA) and of urokinase-type PA (u-PA) activity. PA inhibitor (PAI) activity was higher in the plasma of aged rats, as was t-PA activity in lung and heart.

Rats were treated with either a low dose (1 μg/kg) or a high dose (10 mg/kg) of endotoxin. Both treatments induced a transient phase of increased blood fibrinolytic activity, as evidenced by higher levels of tissue-type plasminogen activator (t-PA) activity and decreased levels of PA inhibitor (PAI) activity. Over time, the fibrinolytic activity decreased, probably due to increased levels of PA inhibitor.

Both the early increase in t-PA activity, and the subsequent increase in PAI activity, were more pronounced in the aged rats, as compared with the younger rats, after the high dose of endotoxin. The aged rats also responded to an injection of interleukin-1β or tumor necrosis factor-α with a larger increase of PAI activity than did the younger rats.

Together the data suggest that, compared to young rats, aged rats have a decreased base-line plasma fibrinolytic activity, while their fibrinolytic system is more responsive to challenge by endotoxin and cytokines.

• References

• 1 Eichenberger E. Fibrinolyse nach intravenoser Injektion bakterieller Pyrogene. Acta Neuroveg 1955; 11: 201-206
• 2 Meneghini P. Fibrinolytic treatment of thrombo-embolic diseases with purified bacterial pyrogens. Acta Haematol 1958; 19: 65-81
• 3 Von Kaulla KN. Intravenous protein-free pyrogen. A powerful fibrinolytic agent in man. Circulation 1958; 17: 187-198
• 4 Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-1172
• 5 van Deventer SJH, Biiller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526
• 6 Fracasso JF, Rotschild AM. Contribution of adrenaline to the fibrinolytic activity evoked by E. coli endotoxin in the rat. Thromb Haemostas 1983; 50: 557-559
• 7 Colucci C, Paramo JA, Collen D. Generation in plasma of a fastacting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-824
• 8 Emeis JJ, Kooistra T. Interleukin-1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-1266
• 9 Dosne AM, Dubor F, Chedid L. Plasminogen activator inhibitor induced by lipopolysaccharide injection in the rat. Zymographic analysis. Fibrinolysis 1987; 1: 45-49
• 10 Siebeck M, Spannagl M, Hoffmann H, Schramm W, Fritz H. Time dependent release of tissue-type plasminogen activator and plasminogen activator inhibitor into the circulation of pigs during shock. Blood Coagul Fibrinol 1991; 2: 459-464
• 11 Morrison DC, Ulevitch RJ. The effects of bacterial endotoxins on host mediation systems. Am J Pathol 1978; 93: 527-618
• 12 Horan MA, Hendriks HFJ, Brouwer A. Organisms under stress: infectious agents and host defences. In: Gerontology. Approaches to Biomedical and Clinical Research. Horan MA, Brouwer A. (eds) Edward Arnold; London: 1990. pp 105-134
• 13 Brouwer A, Horan MA, Barelds RJ, Knook DL. Cellular aging of the reticuloendothelial system. Arch Geront Geriatr 1986; 5: 317-324
• 14 Durham SK, Horan MA, Brouwer A, Barelds RJ, Knook DL. Comparative endotoxin-induced hepatic injury in young and aged rats. J Pathol 1990; 162: 341-349
• 15 Durham SK, Horan MA, Brouwer A, Barelds RJ, Knook DL. Platelet participation in the increased severity of endotoxin-induced pulmonary injury in aged rats. J Pathol 1989; 157: 339-345
• 16 Burek JD. Pathology of aging rats. A morphological and experimental study of the age-associated lesions in aging BN/Bi, WAG/Rij, and (WAG x BN) FI rats. CRC Press; West Palm Beach: 1978
• 17 Gallimore MJ, Tyler HM, Shaw JTB. The measurement of fibrinolysis in the rat. Thromb Diath Haemorrh 1971; 26: 295-310
• 18 Emeis JJ, van den Hoogen CM, Jense D. Hepatic clearance of tissue-type plasminogen activator in rats. Thromb Haemostas 1985; 54: 661-664
• 19 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
• 20 Padro T, Emeis JJ. Effect of different dietary-induced hyperlipaemias on rat plasma fibrinolytic components. Fibrinolysis 1990; 4: 161-167
• 21 Vassalli JD, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987; 214: 187-191
• 22 Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
• 23 Emeis JJ, Lindeman J, Nieuwenhuizen W. Immunoenzyme his-tochemical localization of fibrin degradation products in tissues. Am J Pathol 1981; 103: 337-344
• 24 Mussoni L, Raczka E, Chmielewska J, Donati MB, Latallo ZS. Plasminogen assay in rabbit, rat and mouse plasma using the chromogenic substrate S-2251. Thromb Res 1979; 15: 341-349
• 25 Emeis JJ, Van Houwelingen AC, van den Hoogen CM, Homstra G. A moderate fish intake increases plasminogen activator inhibitor type-1 in human volunteers. Blood 1989; 74: 233-237
• 26 Granelli-Pipemo A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-234
• 27 Padro T, van den Hoogen CM, Emeis JJ. Distribution of tissue-type plasminogen activator (activity and antigen) in rat tissues. Blood Coagul Fibrinol 1991; 1: 601-608
• 28 Van Hinsbergh VWM, Kooistra T, Van den Berg EA, Princen HMG, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1467-1473
• 29 Tranquille N, Emeis JJ. Protein synthesis inhibition by cycloheximide does not affect the acute release of tissue-type plasminogen activator. Thromb Haemostas 1989; 61: 442-447
• 30 Gralnick HR, McKeown LP, Wilson OM, Willimans SB, Elin RJ. Von Willebrand factor release induced by endotoxin. J Lab Clin Med 1989; 113: 118-122
• 31 Novotny MJ, Turrentine MA, Johnson GS, Adams HR. Experimental endotoxemia increases plasma von Willebrand factor antigen concentrations in dogs with and withoug free-radical scavenger therapy. Circ Shock 1987; 23: 205-213
• 32 Tranquille N, Emeis JJ. The simultaneous acute release of tissue-type plasminogen activator and von Willebrand factor in the perfused rat hindleg region. Thromb Haemostas 1990; 63: 454-458
• 33 Quax PHA, van den Hoogen CM, Verheijen JH, Padro T, Zeheb R, Gelehrter TD, van Berkel TJC, Kuiper J, Emeis JJ. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 1990; 265: 15560-15563
• 34 Dosne AM, Dubor F, Lutcher F, Parant M, Chedid L. Tumor necrosis factor (TNF) stimulates plasminogen activator inhibitor (PAI) production by endothelial cells and decreases blood fibrinolytic activity in the rat. Thromb Res 1988; Suppl VII 115-122
• 35 Aillaud MF, Pignol F, Alessi MC, Harle JR, Escande M, Mongin M, Juhan-Vague I. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII :C and in erythrocyte sedimentation rate with age. Thromb Haemostas 1986; 55: 330-332
• 36 Hashimoto Y, Kobayashi A, Yamazaki N, Sugawara Y, Takada Y, Takada A. Relationship between age and plasma t-PA, PA-inhibitor, and PA activity. Thromb Res 1987; 46: 625-633
• 37 Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
• 38 Ranby M, Bergsdorf W, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160-2165
• 39 Siegbahn A, Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb Haemostas 1988; 60: 361-364
• 40 Stegnar M, Keber D, Pentek M, Vene N, Kluft C. Age and sex differences in resting and postocclusion values of tissue plasminogen activator in a healthy population. Fibrinolysis 1988; 2 Suppl [phone]
• 41 Kluft C, Jie AFH, Lowe GDO, Blarney SL, Forbes CD. Association between postoperative hyper-response in t-PA inhibition and deep vein thrombosis. Thromb Haemostas 1986; 56: 107